Similarly, another randomized, double-blinded, placebo-controlled trial carried out on 240 adult participants with T2D assigned to receive curcumin (250 mg/day) or a placebo for 6 months, showed that the intervention group presented increased serum adiponectin and decreased leptin, with an overall reduced atherogenic risk, compared to controls [42]. The gene discussed is LEP; the disease is type 2 diabetes mellitus.